Leidos Biomedical Research Inc Contracts with Department of Health and Human Services
Relationship Overview
Total Contract Value: $13,766,856,827
Contract Count: 83
Average Contract Size: $165.9M
Sole Source Rate: 0%
Small Business Rate: 0%
Spending by Sector
- Other: $7.6B (15 contracts)
- R&D: $5.8B (58 contracts)
- Healthcare: $301.2M (7 contracts)
- Construction: $8.4M (2 contracts)
- IT: $8.2M (1 contracts)
Contracts
- TAS::75 0849::TAS OPER OF GOVT R&D GOCO FACILITIES — $4.8B
- Contract — $2.4B
- NCI OPERATIONAL TASK ORDER — $1.8B
- NCI OPERATIONAL TASK ORDER — $437.4M
- NCI FY25 OPERATIONAL TASK ORDER — $398.9M
- NCI OPERATIONAL TASK ORDER, FY26-FY27 — $327.1M
- NIAID DCR OPERATIONAL TASK ORDER COVID FUNDING IN THE AMOUNT OF $3,706,224 FOR COVID RELATED EFFORTS ON THIS TASK ORDER — $291.2M
- NIAID COVID-19 ACTIV3 — $233.6M
- THE OBJECTIVE OF THIS TASK ORDER SUPPORTS NIAIDS GOAL TO CONDUCT A SERIES OF STANDARDIZED PHASE 1 AND PHASE 2 TRIALS ON NEXT-GENERATION VACCINES TO GENERATE DATA TO INFORM DECISIONS ON WHICH CANDIDATES TO SUPPORT FOR ADVANCED DEVELOPMENT. — $173.3M
- MD NET — $163.5M
- CENTER FOR SEROLOGICAL SCIENCES NETWORK (SERONET) — $143.6M
- ADVANCE UNIVERSAL INFLUENZA VACCINE - FLU MOSAIC VERSION 2 (FLUMOSV2) — $141.7M
- FFRDC SPACE MANAGEMENT TASK ORDER (LEASES) — $126.4M
- NIAID VRC — $121.5M
- DCR IS REQUESTING THE SERVICES OF LEIDOS BIOMEDICAL RESEARCH, INC. TO INITIATE MANAGEMENT, OVERSIGHT, EXECUTION, CLOSEOUT AND PUBLICATION OF FINDINGS OF A PROSPECTIVE OBSERVATIONAL STUDY OF ADULT AND PEDIATRIC PATIENTS WITH UNKNOWN FEBRILE ILLNESS FR — $97.5M
- ON BEHALF OF NIAID-DCR, FACILITATE THE CONDUCT OF TWO, RANDOMIZED TRIALS AS DETAILED BELOW IN I AND II: I. A RANDOMIZED BLINDED CONTROLLED TRIAL OF THE SAFETY AND EFFICACY OF INVESTIGATIONAL THERAPEUTICS FOR THE TREATMENT OF COVID-19 (2,000 SUBJECTS — $89.6M
- ENABLING NCI CLINICAL & RESEARCH DATA SHARING — $80.9M
- IGF::OT::IGF OPERATION OF GOVERNMENT-OWNED CONTRACTOR-OPERATED (GOCO) R&D FACILITIES — $72.8M
- INITIATE THE MANAGEMENT, OVERSIGHT, AND CONDUCT OF THE NIAID DMID CLINICAL TRIAL TITLED "A MULTICENTER, ADAPTIVE, RANDOMIZED BLINDED CONTROLLED TRIAL OF THE SAFETY AND EFFICACY OF INVESTIGATIONAL THERAPEUTICS FOR THE TREATMENT OF COVID-19". — $72.4M
- PDX PANELS FROM COMMON TUMORS — $67.9M
Frequently Asked Questions
How many contracts does Leidos Biomedical Research Inc have with Department of Health and Human Services?
Leidos Biomedical Research Inc has 83 contracts with Department of Health and Human Services worth a combined $13.8B.
What is the average contract size between Leidos Biomedical Research Inc and Department of Health and Human Services?
The average contract size is $165.9M.
What percentage of Leidos Biomedical Research Inc's contracts with Department of Health and Human Services are sole-source?
0% of the contracts are sole-source awards.